Outset Medical First-Quarter Results Demonstrate Strong Growth in Console and Recurring Revenue as Gross Margin Expanded and Cash Use Declined

About this update from Outset Medical, Inc.

[{"type":"image","alt":"Outset Medical, Inc.","displaySize":"","headline":null,"caption":"Outset Medical, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":150,"url":"https://media.zenfs.com/en/globenewswire.com/dbf72cbabf20edef2d3c5e04f8a2ce35"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/81TozlI2nSbjNuKd34NOOQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTIxMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/dbf72cbabf20edef2d3c5e04f8a2ce35","width":300,"height":150}},"lazy":false},{"type":"text","content":"SAN JOSE, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Outset Medical, Inc. (Nasdaq: OM), a medical technology company pioneering a first-of-its-kind technology to reduce the cost and complexity of dialysis, today reported financial results for the first quarter ended March 31, 2025.","length":280,"tagName":"p"},{"type":"text","content":"First Quarter and Recent Highlights","length":35,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net revenue of $29.8 million grew 6% from the prior-year period.","length":64,"tagName":"p"}]},{"val":[{"type":"text","content":"Tablo console revenue grew 23% from the fourth quarter.","length":55,"tagName":"p"}]},{"val":[{"type":"text","content":"Recurring revenue consisting of Tablo consumables and services grew 20% over the prior-year period to $22.7 million. Outset shipped its 3 millionth Tablo treatment during the quarter, adding 1 million treatments over a period of approximately 12 months.","length":253,"tagName":"p"}]},{"val":[{"type":"text","content":"Gross margin was 37.2%. On a non-GAAP basis, gross margin reached 37.6%, an increase of more than 6 percentage points over the prior-year period. Stranded manufacturing overhead costs were approximately a 230-basis point headwind to non-GAAP gross margin in the quarter. Excluding these costs, non-GAAP gross margin would have been approximately 40%.","length":350,"tagName":"p"}]},{"val":[{"type":"text","content":"Demonstrated continued progress toward profitability with net cash used in operating activities declining 44% from the first quarter of 2024.","length":141,"tagName":"p"}]},{"val":[{"type":"text","content":"Reiterated that proposed and recently enacted tariffs are expected to have no impact on the company due to a special exemption Outset received in January for products that serve the chronic...

More updates from Outset Medical, Inc.